Efficacy of idebenone in the Treatment of iRBD into Synucleinopathies (EITRS): rationale, design, and methodology of a randomized, double-blind, multi-center clinical study

BACKGROUND: As the strongest prodromal marker of α-synuclein-specific neurodegeneration, idiopathic REM sleep behavior disorder (iRBD) is becoming a focus of interest in disease-modifying therapy. Idebenone has been widely portrayed as a potent antioxidant targeting mitochondrial dysfunction. Previo...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yuanyuan, Wang, Chunyi, Luo, Ningdi, Chen, Fangzheng, Zhou, Liche, Niu, Mengyue, Kang, Wenyan, Liu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510988/
https://www.ncbi.nlm.nih.gov/pubmed/36172027
http://dx.doi.org/10.3389/fneur.2022.981249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9510988/
https://www.ncbi.nlm.nih.gov/pubmed/36172027
http://dx.doi.org/10.3389/fneur.2022.981249

Ejemplares similares